Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis

A. Affleck (Lead / Corresponding author), A. Goudie, R. Smith

    Research output: Contribution to journalLetter

    3 Citations (Scopus)
    16 Downloads (Pure)

    Abstract

    Methotrexate has historically thought to be able to cause pulmonary fibrosis and this potential side effect is listed in major textbooks, patient information leaflets and national guidelines. This belief is based on a very small number of previously published isolated case reports; however, when these reports are scrutinised, such cases of pulmonary fibrosis arising many years after the introduction of methotrexate could represent other interstitial lung diseases unrelated to methotrexate.2,3 Once dogma is established, it can be difficult to undo. This article is protected by copyright. All rights reserved.

    Original languageEnglish
    Pages (from-to)591-592
    Number of pages2
    JournalClinical and Experimental Dermatology
    Volume44
    Issue number5
    Early online date28 Mar 2019
    DOIs
    Publication statusPublished - Jul 2019

    Fingerprint Dive into the research topics of 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis'. Together they form a unique fingerprint.

  • Cite this